Allscripts Joins with Microsoft to Explore Technology for Clinical Research
CHICAGO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Today, Allscripts (NASDAQ:MDRX), a global leader in health care information technology, announced a collaboration with Microsoft focused on implementing an innovative, integrated model for clinical research, aiming to enhance clinical research design, conduct studies more efficiently and improve the research provider and participant experience.
Leading this effort, Veradigm, a payer and life sciences-focused business unit within Allscripts, has signed a memorandum of understanding with Microsoft to develop an innovative integrated research model, enabling clinical research to be performed through point-of-care technology platforms. The initial focus of this collaboration will be to extend Allscripts’ cloud-based electronic health record (EHR) platforms with innovative technologies focused on enabling integrated research -- for instance point-of-care, automated “match-making” between study protocols and the patients and providers who may qualify for those studies. The joint effort is also expected to include pilot programs to better understand, inform and develop the necessary processes, workflows and compliance framework that may be necessary to support research performed within this new, integrated operating model.
This effort is designed to improve the time to market of new therapies while decreasing the cost of research and development. A major reason for the current inefficiencies in clinical research is that the operating model under which research is conducted today has remained largely unchanged, despite the scientific and technological breakthroughs of the last 30 years.
Interventional clinical trials remain the gold standard, and while real world evidence (RWE) is increasingly used, to date it is largely applied in post market introduction safety scenarios. The value of electronic health records (EHR) can be more fully realized with technologies and workflows to support clinical research and with this new model, research becomes a natural output of the care process.
Stephanie Reisinger, VP & GM at Veradigm explains, “Just as rideshare organizations such as Lyft replaced the traditional specialized taxi driver and dispatch service with technology enabled drivers, we envision a network of technology enabled research clinicians providing an alternative to the roles associated within the traditional clinical trial operating model.”
Recent market events have paved the way for this evolution. In July 2018, the U.S. Food and Drug Administration authored a new guidance document titled “Use of Electronic Health Record Data in Clinical Investigations”, which encourages modernization of clinical research by leveraging new technologies and Electronic Health Records (EHRs). In addition, in December 2018, the FDAreleased the “Framework for FDA’s Real-World Evidence Program”, describing the use of data captured through routine care delivery (real world data) supporting approval of new indications for approved drugs, and post approval study requirements.
“New technologies and models have the potential to drastically improve the clinical research process,” said Chris Sakalosky, vice president, U.S. Health and Life Sciences at Microsoft. “Working alongside industry leaders like Veradigm, we believe solutions powered by Microsoft Azure and AI will help biopharmaceutical and clinical research organizations better conduct research, and, in the future, improve quality of life.”
Tom Langan, CEO of Veradigm said, “By integrating research at the point of care, we have the potential to lower costs, increase efficiencies, and remove bottlenecks that inhibit research, all while improving the welfare of patients. The barriers preventing this shift have now largely been removed – what is needed is a commitment to developing the technologies, workflows, processes and compliance frameworks to support it. Veradigm and Microsoft are stepping up to this commitment.”
Langan continued, “In partnership with Microsoft, Veradigm is committed to a holistic approach to developing the platform that supports integrated clinical research. The teams are prepared to work with the industry and regulators to ensure that the promise of this new approach is fully realized, bringing the practice of clinical research into the 21st Century.”
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved.
Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
For more information contact:
Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
